Literature DB >> 12517655

Physician specialty is significantly associated with hormone replacement therapy use.

Barcey T Levy1, Justine M Ritchie, Elaine Smith, Teresa Gray, Wei Zhang.   

Abstract

OBJECTIVE: To compare the characteristics of postmenopausal women seen by gynecologists versus family physicians and to determine factors associated with current hormone replacement therapy (HRT) use.
METHODS: We conducted a cross-sectional study of 426 postmenopausal women seen for their annual examination at university clinics. Logistic regression was used to identify predictors of current versus never HRT use.
RESULTS: Overall, 60% of women recruited in family practice clinics and 69% in gynecology clinics were current HRT users. Significant, positive, multivariable predictors of HRT use were gynecology versus family practice clinic attendance (odds ratio [OR] 2.6, 95% confidence interval [CI] 1.4, 4.6), surgical menopause (OR 2.3, 95% CI 1.2, 4.6), history of depression (OR 2.3, 95% CI 1.2, 4.7), at least two live births (OR 2.1, 95% CI 1.1, 4.0), and current alcohol use (OR 1.8, 95% CI 1.04, 3.2). Significant, negative, multivariable predictors were increasing age (60-70 years versus less than 60 years, OR 0.4, 95% CI 0.2, 0.8; 70 years or older versus less than 60 years, OR 0.4, 95% CI 0.2, 0.9) and history of breast cancer (OR 0.04, 95% CI 0.01, 0.14). Sociodemographic factors, smoking status, number of self-reported medical conditions, number of prescription medications besides HRT, oral contraceptive use, history of hypertension, and exercise level were tested as covariates and did not enter the model.
CONCLUSION: Although current HRT use rates between clinics were similar and higher than national averages, we found that the adjusted odds of current HRT use among women receiving care from gynecologists was 2.6 times that among women receiving care from family physicians. This practice variation may reflect physicians' uncertainty surrounding the preventive value of HRT.

Entities:  

Mesh:

Year:  2003        PMID: 12517655     DOI: 10.1016/s0029-7844(02)02381-5

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  6 in total

1.  Self-reported changes in providers' hormone therapy prescribing and counseling practices after the Women's Health Initiative.

Authors:  Susan L Lakey; Susan D Reed; Andrea Z LaCroix; Lou Grothaus; Katherine M Newton
Journal:  J Womens Health (Larchmt)       Date:  2010-11-09       Impact factor: 2.681

2.  Socio-demographic and geographic variations in the utilization of hormone therapy in older women with breast cancer after Medicare Part-D coverage.

Authors:  Xin Wang; Xianglin L Du
Journal:  Med Oncol       Date:  2015-04-03       Impact factor: 3.064

3.  Soluble CD14 and fracture risk.

Authors:  M Bethel; P Bůžková; H A Fink; J A Robbins; J A Cauley; J Lee; J I Barzilay; D I Jalal; L D Carbone
Journal:  Osteoporos Int       Date:  2015-12-11       Impact factor: 4.507

4.  Determinants of hormone therapy discontinuation among female veterans nationally.

Authors:  Sally G Haskell; Bevanne Bean-Mayberry; Joseph L Goulet; Melissa Skanderson; Chester B Good; Amy C Justice
Journal:  Mil Med       Date:  2008-01       Impact factor: 1.437

5.  Changes of the prescription of hormone therapy in menopausal women: an observational study in Taiwan.

Authors:  Weng-Foung Huang; Yi-Wen Tsai; Fei-Yuan Hsiao; Wen-Chun Liu
Journal:  BMC Public Health       Date:  2007-04-17       Impact factor: 3.295

6.  Variation in the psychosocial determinants of the intention to prescribe hormone therapy prior to the release of the Women's Health Initiative trial: a survey of general practitioners and gynaecologists in France and Quebec.

Authors:  France Legare; Gaston Godin; Virginie Ringa; Sylvie Dodin; Lucile Turcot; Joanna Norton
Journal:  BMC Med Inform Decis Mak       Date:  2005-09-08       Impact factor: 2.796

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.